Long-Term Response to Gemcitabine, Cisplatin, and Nab-Paclitaxel Followed by Maintenance Therapy for Advanced Gallbladder Cancer: A Case Report and Literature Review

BACKGROUND: Gallbladder cancer (GBC) is the most common and devastating tumor type of biliary tract cancer (BTC) with poor outcomes. A new combined regimen of gemcitabine, cisplatin, plus nab-paclitaxel is currently considered an effective option for patients with advanced BTC following the results...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ting, Li, Qing, Zhang, Wenjie, Zhu, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8523915/
https://www.ncbi.nlm.nih.gov/pubmed/34676166
http://dx.doi.org/10.3389/fonc.2021.733955

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8523915/
https://www.ncbi.nlm.nih.gov/pubmed/34676166
http://dx.doi.org/10.3389/fonc.2021.733955

Ejemplares similares